본문 바로가기
KERD
논문KCI 등재

Clostridium difficile Infection: A Worldwide Disease

Kristin E. Burke|J. Thomas Lamont
거트앤리버 소화기연관학회협의회|2014.01|Gut and Liver|제8권 제1호|pp. 1-6

2

조회

0

다운로드

10

인용

0

참고문헌

키워드

AsiaEpidemiologyReviewClostridium difficile

초록

Clostridium difficile, an anaerobic toxigenic bacterium, causes a severe infectious colitis that leads to significant morbidity and mortality worldwide. Both enhanced bacterial toxins and diminished host immune response contribute to symptomatic disease. C. difficile has been a well-established pathogen in North America and Europe for decades, but is just emerging in Asia. This article reviews the epidemiology, microbiology, pathophysiology, and clinical management of C. difficile. Prompt recognition of C. difficile is necessary to implement appropriate infection control practices.

Abstract

Clostridium difficile, an anaerobic toxigenic bacterium, causes a severe infectious colitis that leads to significant morbidity and mortality worldwide. Both enhanced bacterial toxins and diminished host immune response contribute to symptomatic disease. C. difficile has been a well-established pathogen in North America and Europe for decades, but is just emerging in Asia. This article reviews the epidemiology, microbiology, pathophysiology, and clinical management of C. difficile. Prompt recognition of C. difficile is necessary to implement appropriate infection control practices.

참고문헌 (55)

  1. Edlund C, "Effect of quinolones on intestinal ecology", Drugs, 58(2), pp.65~70 (1999)
  2. Johnson S., "Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes", J Infect, 58, pp.403~410 (2009)
  3. Pépin J, "Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec", Clin Infect Dis, 41, pp.1254~1260 (2005)
  4. Kyne L, "Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A", N Engl J Med, 342, pp.390~397 (2000)
  5. Kyne L, "Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea", Lancet, 357, pp.189~193 (2001)
  6. Johnson S, "Nosocomial Clostridium difficile colonisation and disease", Lancet, 336, pp.97~100 (1990)
  7. Simor AE, "Diagnosis, management, and prevention of Clostridium difficile infection in long-term care facilities: a review", J Am Geriatr Soc, 58, pp.1556~1564 (2010)
  8. Kelly CP, "Clostridium difficile: more difficult than ever", N Engl J Med, 359, pp.1932~1940 (2008)
  9. Vedantam G, "Viswanathan VK,. Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response", Gut Microbes, 3, pp.121~134 (2012)
  10. Pothoulakis C, "Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins", Am J Physiol Gastrointest Liver Physiol, 280, pp.G178~G183 (2001)
  11. Schwan C, "Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria", PLoS Pathog, 5, pp.e1000626~ (2009)
  12. Brandt LJ., "American Journal of Gastroenterology Lecture: intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection", Am J Gastroenterol, 108, pp.177~185 (2013)
  13. Nord CE, "Impact of antimicrobial agents on the gastrointestinal microflora and the risk of infections", Am J Med, 76(5A), pp.99~106 (1984)
  14. Chang JY, "Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea", J Infect Dis, 197, pp.435~438 (2008)
  15. Jangi S, "Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life", J Pediatr Gastroenterol Nutr, 51, pp.2~7 (2010)
  16. Solomon K, "Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses", J Med Microbiol, 62(Pt 9), pp.1453~1460 (2013)
  17. MacCannell DR, "Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada", J Clin Microbiol, 44, pp.2147~2152 (2006)
  18. McDonald LC, "An epidemic, toxin gene-variant strain of Clostridium difficile", N Engl J Med, 353, pp.353~2433 (2005)
  19. Warny M, "Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe", Lancet, 366, pp.1079~1084 (2005)
  20. "Clostridium difficile infections (CDI) in hospital stays" (2006)[URL]
  21. Goorhuis A, "Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078", Clin Infect Dis, 47, pp.1162~1170 (2008)
  22. Kim YS, "Incidence and clinical features of Clostridium difficile infection in Korea: a nationwide study", Epidemiol Infect, 141, pp.189~194 (2013)
  23. Huang H, "Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm", Clin Microbiol Infect, 15, pp.1170~1173 (2009)
  24. Kim H, "Increasing prevalence of toxin A-negative, toxin B-positive isolates of Clostridium difficile in Korea: impact on laboratory diagnosis", J Clin Microbiol, 46, pp.1116~1117 (2008)
  25. Shin BM, "Multicentre study of the prevalence of toxigenic Clostridium difficile in Korea: results of a retrospective study 2000-2005", J Med Microbiol, 57(Pt 6), pp.697~701 (2008)
  26. Hawkey PM, "Molecular epidemiology of Clostridium difficile infection in a major Chinese hospital: an under recognised problem in Asia?", J Clin Microbiol, 51, pp.3308~3313 (2013)
  27. Dong D, "Antimicrobial susceptibility and resistance mechanisms of clinical Clostridium difficile from a Chinese tertiary hospital", Int J Antimicrob Agents, 41, pp.80~84 (2013)
  28. Kim J, "Epidemiology of Clostridium difficile infections in a tertiary-care hospital in Korea", Clin Microbiol Infect, 19, pp.521~527 (2013)
  29. Cheng VC, "Clostridium difficile isolates with increased sporulation: emergence of PCR ribotype 002 in Hong Kong", Eur J Clin Microbiol Infect Dis, 30, pp.1371~1381 (2011)
  30. Ingle M, "Clostridium difficile as a cause of acute diarrhea: a prospective study in a tertiary care center", Indian J Gastroenterol, 32, pp.179~183 (2013)
  31. Haider Naqvi SA, "Clostridium difficile postantibiotic diarrhoea diagnosis", J Coll Physicians Surg Pak, 22, pp.640~643 (2012)
  32. Hsu LY, "Decline in Clostridium difficile-associated disease rates in Singapore public hospitals, 2006 to 2008", BMC Res Notes, 4, pp.77~ (2011)
  33. Lim PL, "Increasing incidence of Clostridium difficile-associated disease, Singapore", Emerg Infect Dis, 14, pp.1487~1489 (2008)
  34. Hassan SA, "Prevalence of Clostridium difficile toxin in diarhoeal stool samples of patients from a tertiary hospital in North Eastern Penisular Malaysia", Med J Malaysia, 67, pp.402~405 (2012)
  35. Wongwanich S, "Detection of Clostridium difficile toxin A and B genes from stool samples of Thai diarrheal patients by polymerase chain reaction technique", J Med Assoc Thai, 86, pp.970~975 (2003)
  36. Warren CA, "Clostridium difficile and Entamoeba histolytica infections in patients with colitis in the Philippines", Trans R Soc Trop Med Hyg, 106, pp.424~428 (2012)
  37. Zar FA, "A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity", Clin Infect Dis, 45, pp.302~307 (2007)
  38. Surawicz CM, "Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections", Am J Gastroenterol, 108, pp.478~498 (2013)
  39. Berg AM, "Clostridium difficile infection in the inflammatory bowel disease patient", Inflamm Bowel Dis, 19, pp.194~204 (2013)
  40. Issa M, "Impact of Clostridium difficile on inflammatory bowel disease", Clin Gastroenterol Hepatol, 5, pp.345~351 (2007)
  41. Nguyen GC, "A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients", Am J Gastroenterol, 103, pp.1443~1450 (2008)
  42. Khanna S, "Acute kidney injury is an independent marker of severity in Clostridium difficile infection: a nationwide survey", J Clin Gastroenterol, 47, pp.481~484 (2013)
  43. Collins DA, "Epidemiology of Clostridium difficile infection in Asia", Antimicrob Resist Infect Control, 2, pp.21~ (2013)
  44. Goldenberg JZ, "Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children", Cochrane Database Syst Rev, 5, pp.CD006095~ (2013)
  45. Donald RG, "A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile", Microbiology, 159(Pt 7), pp.1254~1266 (2013)
  46. Foglia G, "Clostridium difficile: development of a novel candidate vaccine", Vaccine, 30, pp.4307~4309 (2012)
  47. Leuzzi R, "Protective efficacy induced by recombinant Clostridium difficile toxin fragments", Infect Immun, 81, pp.2851~2860 (2013)
  48. Riedmann EM, "Human vaccines & immunotherapeutics: news", Hum Vaccin Immunother, 9, pp.2034~2037 (2013)
  49. Cornely OA, "Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial", Lancet Infect Dis, 12, pp.281~289 (2012)
  50. Louie TJ, "Fidaxomicin versus vancomycin for Clostridium difficile infection", N Engl J Med, 364, pp.422~431 (2011)
  51. Bartsch SM, "Is fidaxomicin worth the cost? An economic analysis", Clin Infect Dis, 57, pp.555~561 (2013)
  52. Johnson S, "Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin", Clin Infect Dis, 44, pp.846~848 (2007)
  53. Johnson S, "Fidaxomicin “chaser” regimen following vancomycin for patients with multiple Clostridium difficile recurrences", Clin Infect Dis, 56, pp.309~310 (2013)
  54. Burke KE, "Fecal transplantation for recurrent Clostridium difficile infection in older adults: a review", J Am Geriatr Soc, 61, pp.1394~1398 (2013)
  55. van Nood E, "Duodenal infusion of donor feces for recurrent Clostridium difficile", N Engl J Med, 368, pp.407~415 (2013)

관련 논문AI추천

Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and PreventionJung Hoon Song, You Sun Kim거트앤리버 소화기연관학회협의회 · Gut and Liver2019 · 제13권 제1호Clostridium difficile 감염의 역학 및 치료배현주대한감염학회 · Infection and Chemotherapy2010 · 제42권 제6호Clinical and Microbiological Risk Factors for Clinical and Microbiological Risk Factors for Severe Clostridioides difficile Infections김도균, 김영아, 김희정, 유창승, 정석훈대한임상미생물학회 · Annals of Clinical Microbiology2022 · 제25권 제1호A Case of Toxic Megacolon Caused by Clostridium difficile Infection and Treated with Fecal Microbiota Transplantation강동훈, 권태근, 김경훈, 김상우, 김진수, 문성진, 박성수, 반태현, 성현진, 이경진거트앤리버 소화기연관학회협의회 · Gut and Liver2015 · 제9권 제2호Fecal Calprotectin Level Reflects the Severity of Clostridium difficile Infection김지은, 김형선, 김희정, 오현주, 용동은, 이경원, 정석훈, 황연지대한진단검사의학회 · Annals of Laboratory Medicine2017 · 제37권 제1호Emergence of Clostridium difficile Ribotype 027 in Korea김희정, 문희원, 이경원, 이양순, 임채승, 정윤섭대한진단검사의학회 · Annals of Laboratory Medicine2011 · 제31권 제3호

이 간행물의 다른 논문 (16건)

Delayed Flumazenil Injection after Endoscopic Sedation Increases Patient Satisfaction Compared with Immediate Flumazenil Injection신용운, 방병욱, 박신구, 권계숙, 정석, 김형길, 이돈행, 정현정pp. 7-12The Expression of Multiple Proteins as Prognostic Factors in Colorectal Cancer: Cathepsin D, p53, COX-2, Epidermal Growth Factor Receptor, C-erbB-2, and Ki-67이인규, 이윤석, 이연수, 시윤, 오승택, 권택수, 신일용, 성나영pp. 13-23Evaluation of Antibody Response to Polysaccharide Vaccine and Switched Memory B Cells in Pediatric Patients with Inflammatory Bowel DiseaseKhadije Soleimani, Habib Soheili, Nima Parvaneh, Behzad Darabi, Rasoul Nasiri Kalmarzi, Shabnam Pourhamdi, Hassan Abolhassani, Babak Mirminachi, Nima Rezaei, Gholamhossein Fallahi, Asghar Aghamohammadi, Ahmad Khodadad, Mojtaba Hashemi, Payam Mohammadinejad, Hossein Asgarian-Omran, Mehri Najafi, Fatemeh Farhmand, Farzaneh Motamedpp. 24-28Ulcerative Colitis and Immunoglobulin G4Terumi Kamisawa, Sawako Kuruma, Taku Tabata, Kazuro Chiba, Shinichiro Horiguchi, Go Kuwata, Junko Fujiwara, Hideto Egashira, Seiichi Hara, Kumiko Momma, Takeo Arakawa, Koichi Koizumi, Takashi Fujiwarapp. 29-34The Relationship between Gastroesophageal Reflux Disease and Chronic Periodontitis김태윤, 김형훈, 송준영, 조은주pp. 35-40
원문 보기